Liraglutide vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog with 97% homology to native human GLP-1. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for obesity. Liraglutide has a shorter half-life than semaglutide (13 hours vs 7 days), requiring daily rather than weekly dosing.
Full details →Tirzepatide
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | Tirzepatide |
|---|---|---|
| Mechanism | Liraglutide binds to the GLP-1 receptor, activating the same pathways as native GLP-1: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. A C-16 fatty acid (palmitic acid) attached to Lys26 via a glutamic acid spacer enables albumin binding, extending the half-life from ~2 minutes (native GLP-1) to ~13 hours. Less potent albumin binding and shorter half-life compared to semaglutide necessitates once-daily dosing. | Tirzepatide is based on the GIP peptide sequence with modifications enabling dual agonism at both GIP and GLP-1 receptors. GIP receptor activation enhances the effects of GLP-1 signaling: (1) potentiated insulin secretion beyond GLP-1 alone, (2) improved beta-cell function, (3) enhanced adipose tissue signaling that may improve fat metabolism, (4) potential protection against GLP-1-induced nausea via GIP receptor activity. The peptide has a C20 fatty diacid moiety enabling albumin binding and once-weekly dosing (half-life ~5 days). The dual mechanism explains the superior weight loss and glycemic outcomes compared to selective GLP-1 agonists. |
| Typical Dosage | For weight management (Saxenda): start at 0.6 mg daily for 1 week. Increase by 0.6 mg weekly until reaching 3.0 mg daily maintenance dose. For type 2 diabetes (Victoza): start at 0.6 mg daily for 1 week, increase to 1.2 mg. May increase to 1.8 mg if additional glycemic control is needed. | For weight management (Zepbound): start at 2.5 mg weekly for 4 weeks. Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg. May increase to 12.5 mg, then maximum 15 mg weekly. For type 2 diabetes (Mounjaro): same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response. |
| Administration | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Administer once daily at any time, independent of meals. Store pens refrigerated before first use; after first use, store at room temperature or refrigerated for up to 30 days. | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior. |
| Side Effects | Very common (>10%): nausea (up to 40%), diarrhea, constipation, vomiting, decreased appetite, dyspepsia, abdominal pain. Higher rate of daily GI symptoms compared to weekly GLP-1s due to daily dosing peaks. Common (1-10%): headache, dizziness, fatigue, injection site reactions, increased heart rate. | Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation. |
| Best For |
What They Have in Common
Liraglutide, Tirzepatide are both commonly used for:
Key Differences
Unique to Liraglutide:
Detailed Analysis
Commonalities
Both Liraglutide and Tirzepatide are commonly used for Fat Loss.
Which Should You Choose?
Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.
Ready to Learn More?
Looking for trusted sources?